Atorvastatin
- Generic Name
- Atorvastatin
- Brand Names
- Atorvaliq, Caduet, Lipitor, Lypqozet
- Drug Type
- Small Molecule
- Chemical Formula
- C33H35FN2O5
- CAS Number
- 134523-00-5
- Unique Ingredient Identifier
- A0JWA85V8F
- Background
Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylg...
- Indication
Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.
...
- Associated Conditions
- Anginal Pain, Cardiovascular Complications, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Coronary artery thrombosis, Dysbetalipoproteinemia, Fredrickson Type III lipidemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hospitalizations, Hypertension, Essential Hypertension, Hypertriglyceridemias, Mixed Dyslipidemias, Mixed Hyperlipidemia, Myocardial Infarction, Non-familial hypercholesterolemia, Nonfatal Myocardial Infarction, Postoperative Thromboembolism, Primary Hypercholesterolemia, Stroke, Thrombosis, Transient Ischemic Attack, Elevation of serum triglyceride levels, Heterozygous familial hyperlipidemia, Non-familial hyperlipidemia, Primary Hyperlipidemia, Revascularization procedures
- Associated Therapies
- -
Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs
- Conditions
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Viriom
- Target Recruit Count
- 56
- Registration Number
- NCT03709355
- Locations
- 🇷🇺
Central Clinical City Hospital, Reutov, Moscow Region, Russian Federation
Prediction and Prevention of Asymptomatic Cardiovascular Insult in Type 1 Diabetic Children: Comparative Effectiveness of Cardioprotective Drugs
- Conditions
- Interventions
- First Posted Date
- 2018-09-06
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 150
- Registration Number
- NCT03660293
- Locations
- 🇪🇬
Faculty of Medicine- Tanta University, Tanta, Gharbia, Egypt
Impact of Nurse-led Programme With Carotid Ultrasound on Addressing Cardiovascular Risk in Patients With Arthritis
- Conditions
- Interventions
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2019-07-25
- Lead Sponsor
- Chinese University of Hong Kong
- Registration Number
- NCT03625089
- Locations
- 🇭🇰
Department of Medicine and Therapeutics, Hong Kong, Hong Kong
Lipid-lowering Therapy Individualization
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2019-09-03
- Lead Sponsor
- Université Catholique de Louvain
- Target Recruit Count
- 75
- Registration Number
- NCT03604471
- Locations
- 🇧🇪
Cliniques universitaires Saint-Luc, Brussels, Belgium
A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies
- Conditions
- Interventions
- First Posted Date
- 2018-06-18
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Joaquina Baranda
- Target Recruit Count
- 50
- Registration Number
- NCT03560882
- Locations
- 🇺🇸
University of Kansas Cancer Center - CRC, Fairway, Kansas, United States
An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
- Conditions
- Interventions
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 153
- Registration Number
- NCT03510884
- Locations
- 🇪🇸
Investigational Site Number :7240003, Pamplona, Navarra, Spain
🇵🇱Investigational Site Number :6160002, Gdansk, Pomorskie, Poland
🇲🇽Investigational Site Number :4840007, Oaxaca, Mexico
An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT03510715
- Locations
- 🇩🇰
Investigational Site Number 2080001, Viborg, Denmark
🇪🇸Investigational Site Number 7240001, A Coruna, Spain
🇸🇮Investigational Site Number 7050001, Ljubljana, Slovenia
The Combination of Atorvastatin, Acetylcysteine and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2018-03-09
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT03460808
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China
Efficacy and Safety Study of the HS-25 Combination With Atorvastatin in Subjects With Hypercholesterolemia in Coronary Heart Diseases
- Conditions
- Interventions
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
- Target Recruit Count
- 255
- Registration Number
- NCT03433196
Safety and Efficacy of Statins for Chinese Patients With Dyslipidemia
- First Posted Date
- 2018-02-01
- Last Posted Date
- 2018-02-01
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 10000
- Registration Number
- NCT03418974
- Locations
- 🇨🇳
School of Public Health, Fudan University, Shanghai, Shanghai, China
🇨🇳Heart Center of Peking University People's Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.